Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of the 2022 ACR/EULAR Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis With Disease Activity and Damage Accrual: A Retrospective Cohort Study.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same author

Outbreak of invasive meningococcal disease caused by a meningococcus serogroup B expressing a rare <i>porA</i> genosubtype (19-54, 15), Spain, March to April 2024.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2025
Same author

Repeat Expansions in PLIN4 Cause Autosomal Dominant Vacuolar Myopathy With Sarcolemmal Features.

Annals of clinical and translational neurology·2025
Same author

Comparative analysis of the use of autologous exosomes and platelet-derived growth factors in women with premature ovarian insufficiency and infertility: A prospective, randomized, observational, analytical study.

Regenerative therapy·2025
Same author

Neuroimmunomodulation induced by mud-bath therapy: clinical benefits and bioregulation of the innate/inflammatory responses induced by a peloid enriched with rosmarinic acid in elderly patients with osteoarthritis.

International journal of biometeorology·2025
Same author

A large-scale sORF screen identifies putative microproteins involved in cancer cell fitness.

iScience·2025

Related Experiment Video

Updated: Jun 18, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Hypocomplementemic urticarial vasculitis syndrome.

Luis J Jara1, Carmen Navarro, Gabriela Medina

  • 1Director of Education and Research, Hospital de Especialidades Centro Medico La Raza, Seris/Zaachila S/N Colonia La Raza, ZP 02990, Mexico City, Mexico. luis_jara_quezada@hotmail.com

Current Rheumatology Reports
|November 20, 2009
PubMed
Summary
This summary is machine-generated.

Hypocomplementemic urticarial vasculitis syndrome (HUVS) is a rare immune condition causing hives and low complement levels. Early diagnosis and treatment with immunosuppressants are crucial for managing this serious autoimmune disease.

Related Experiment Videos

Last Updated: Jun 18, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

Area of Science:

  • Immunology
  • Rheumatology
  • Dermatology

Background:

  • Hypocomplementemic urticarial vasculitis syndrome (HUVS) is an uncommon immune complex-mediated disorder.
  • It is characterized by chronic urticaria, persistent acquired hypocomplementemia, and leukocytoclastic vasculitis.
  • HUVS presents with diverse systemic manifestations, including angioedema, arthritis, glomerulonephritis, and uveitis, persisting for at least six months.

Purpose of the Study:

  • To summarize the key features of Hypocomplementemic urticarial vasculitis syndrome.
  • To highlight diagnostic markers and treatment strategies for HUVS.
  • To underscore the potential for significant morbidity and mortality associated with HUVS.

Main Methods:

  • Review of existing literature on Hypocomplementemic urticarial vasculitis syndrome.
  • Analysis of clinical and laboratory findings associated with HUVS.
  • Evaluation of treatment outcomes and prognostic factors in HUVS patients.

Main Results:

  • HUVS is defined by urticaria and hypocomplementemia, with low classical complement pathway components (C1q, C2, C3, C4).
  • The presence of anti-C1q antibodies in serum is a key diagnostic marker.
  • Systemic involvement includes vasculitis, arthritis, and organ-specific damage, contributing to morbidity.

Conclusions:

  • Hypocomplementemic urticarial vasculitis syndrome requires prompt diagnosis and management.
  • Treatment typically involves corticosteroids and immunosuppressive agents tailored to disease severity.
  • Effective management is essential to mitigate the significant morbidity and mortality risks, particularly from pulmonary and laryngeal complications.